Royalty Pharma Plc Stock Market Value
| RPRX Stock | USD 45.19 0.39 0.87% |
| Symbol | Royalty |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Royalty Pharma. Anticipated expansion of Royalty directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Royalty Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.09 | Dividend Share 0.88 | Earnings Share 1.78 | Revenue Per Share | Quarterly Revenue Growth 0.048 |
Understanding Royalty Pharma Plc requires distinguishing between market price and book value, where the latter reflects Royalty's accounting equity. The concept of intrinsic value - what Royalty Pharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Royalty Pharma's price substantially above or below its fundamental value.
It's important to distinguish between Royalty Pharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Royalty Pharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Royalty Pharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Royalty Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Royalty Pharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Royalty Pharma.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Royalty Pharma on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Royalty Pharma Plc or generate 0.0% return on investment in Royalty Pharma over 90 days. Royalty Pharma is related to or competes with Genmab AS, United Therapeutics, Incyte, Fresenius Medical, Summit Therapeutics, Smith Nephew, and Roivant Sciences. Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutic... More
Royalty Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Royalty Pharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Royalty Pharma Plc upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 1.19 | |||
| Information Ratio | 0.1551 | |||
| Maximum Drawdown | 5.25 | |||
| Value At Risk | (1.50) | |||
| Potential Upside | 2.01 |
Royalty Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Royalty Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Royalty Pharma's standard deviation. In reality, there are many statistical measures that can use Royalty Pharma historical prices to predict the future Royalty Pharma's volatility.| Risk Adjusted Performance | 0.1773 | |||
| Jensen Alpha | 0.2136 | |||
| Total Risk Alpha | 0.1527 | |||
| Sortino Ratio | 0.1491 | |||
| Treynor Ratio | 0.5851 |
Royalty Pharma February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1773 | |||
| Market Risk Adjusted Performance | 0.5951 | |||
| Mean Deviation | 0.9122 | |||
| Semi Deviation | 0.9424 | |||
| Downside Deviation | 1.19 | |||
| Coefficient Of Variation | 462.79 | |||
| Standard Deviation | 1.15 | |||
| Variance | 1.32 | |||
| Information Ratio | 0.1551 | |||
| Jensen Alpha | 0.2136 | |||
| Total Risk Alpha | 0.1527 | |||
| Sortino Ratio | 0.1491 | |||
| Treynor Ratio | 0.5851 | |||
| Maximum Drawdown | 5.25 | |||
| Value At Risk | (1.50) | |||
| Potential Upside | 2.01 | |||
| Downside Variance | 1.43 | |||
| Semi Variance | 0.8882 | |||
| Expected Short fall | (1.01) | |||
| Skewness | (0.41) | |||
| Kurtosis | (0.05) |
Royalty Pharma Plc Backtested Returns
Royalty Pharma appears to be very steady, given 3 months investment horizon. Royalty Pharma Plc maintains Sharpe Ratio (i.e., Efficiency) of 0.21, which implies the firm had a 0.21 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Royalty Pharma Plc, which you can use to evaluate the volatility of the company. Please evaluate Royalty Pharma's Risk Adjusted Performance of 0.1773, semi deviation of 0.9424, and Coefficient Of Variation of 462.79 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Royalty Pharma holds a performance score of 16. The company holds a Beta of 0.41, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Royalty Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Royalty Pharma is expected to be smaller as well. Please check Royalty Pharma's maximum drawdown, skewness, as well as the relationship between the Skewness and day typical price , to make a quick decision on whether Royalty Pharma's historical price patterns will revert.
Auto-correlation | -0.22 |
Weak reverse predictability
Royalty Pharma Plc has weak reverse predictability. Overlapping area represents the amount of predictability between Royalty Pharma time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Royalty Pharma Plc price movement. The serial correlation of -0.22 indicates that over 22.0% of current Royalty Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.22 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 3.85 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.